Periprocedural myonecrosis or infarction are associated with short, intermediate, and long
term adverse outcomes. Previous study indicated 12.6% of patients suffered a peri-procedural
CK-MB rise by overlapping use of drug-eluting stents for long coronary lesions. Here the
investigators hypothesize that peri-procedural use of tirofiban could reduce the occurrence
of periprocedural infarciton in elective patients with long coronary lesions treated by
overlapping use of drug-eluting stents.